What is the latest status of the project “BioVac - Pfizer”?

The status recorded for “BioVac - Pfizer” is active.

Who are the main government, EPC, and private stakeholders for “BioVac - Pfizer”?

Taiyo maps the stakeholders of “BioVac - Pfizer”: government bodies (International Finance Corporation (IFC)).

Where can I verify the source and access all details for “BioVac - Pfizer”?

This Taiyo project page references International Finance Corporation (IFC) along with the original URL (https://disclosures.ifc.org/project-detail/ESRS/46582/biovac-pfizer). Taiyo standardizes official data into a consistent, searchable project profile.

BioVac - Pfizer

Sector: Raw Materials • Location: South Africa

Source: International Finance Corporation (IFC)

Project

Active

The project entails a financing package of $25 million to BioVac Limited (“BioVac” or the “Company”) a South African based biopharma company to support their vaccine manufacturing capabilities. The Company is planning to expand their operations through a 2-part project the first of which involves manufacturing the Pfizer COVID-19 vaccine (fill and finish only) and IFC will finance this via a $7 m

Project Information

4 Q

The project “BioVac - Pfizer” is an infrastructure initiative in the Raw Materials sector, located in South Africa. Taiyo aggregates data on it from International Finance Corporation (IFC).

Want to explore the full details? View the full report

Participants

Sponsoring Agency	Obfuscated Data
Company	Obfuscated Data

Status

Original status	active
Taiyo status	Obfuscated Data
Taiyo last update	00-00-0000
Available timestamps	00-00-0000
Available timestamp type	Obfuscated Data

Contact

Contact name	Obfuscated Data
Phone	0000000000
Email	ObfuscatedData@email.com
Address	Obfuscated Data, Obfuscated data, obfuscated data, Obfuscated data

Description

Description	The project entails a financing package of $25 million to BioVac Limited (“BioVac” or the “Company”) a South African based biopharma company to support their vaccine manufacturing capabilities. The Company is planning to expand their operations through a 2-part project the first of which involves manufacturing the Pfizer COVID-19 vaccine (fill and finish only) and IFC will finance this via a $7 million loan. The second component includes construction of new multi-vaccine facility. IFC will provide $500k funding to support the bankable feasibility study for this facility (~130 million doses annually) and provide $7.5 million in equity (~12.5% stake) and a $10 million loan to support the actual development. The main facility at BioVac consists of 6 buildings spanning some 5,500 m2 in total surface area. A new building has been constructed (building E) to house the “freezer farm” as required for the storage of vaccines. In addition, a 50-tonne capacity liquid nitrogen tank has been installed.
Original sub-sector	Obfuscated
Original Currency	USD
Original budget	000000000000000
Procurement method	Obfuscated Data
Budget	000000000000000

Location

Region	Obfuscated
Country	Obfuscated
State	Obfuscated Data
County	Obfuscated
Location	Obfuscated Data, Obfuscated data, obfuscated data, Obfuscated data

Source

Source reliability	High
Data quality score	100%
Source	Obfuscated Data
URL	obfuscated_data,obfuscateddata.com

More Details

Project Type	Obfuscated Data
Article Published Date	Obfuscated Data

BioVac - Pfizer

Project Information FAQ

Project Information